araag2/HINT huggingface dataset:
Clinical trial NCT03474042 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: glpg2737, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subject ≥18 years of age on the day of signing the ICF.

          -  A confirmed clinical diagnosis of CF and homozygous for the F508del CFTR mutation.

          -  Stable intake of physician prescribed Orkambi (lumacaftor 400 mg/ivacaftor 250 mg
             b.i.d.) for at least 12 weeks prior to the first study drug administration, and
             planned continuation of Orkambi for the duration of the study.

          -  FEV1 ≥40% of predicted normal for age, gender and height at screening (pre- or
             postbronchodilator).

          -  Sweat chloride concentration ≥60 mmol/L at screening.

        Exclusion Criteria:

          -  History of serious allergic reaction to any drug as determined by the investigator
             (e.g., anaphylaxis requiring hospitalization) and/or known sensitivity to any
             component of the study drug.

          -  History of clinically meaningful unstable or uncontrolled chronic disease that makes
             the subject unsuitable for inclusion in the study in the opinion of the investigator.

          -  Unstable pulmonary status or respiratory tract infection (including rhinosinusitis)
             requiring a change in therapy within 4 weeks prior to the first study drug
             administration.

          -  History of hepatic cirrhosis with portal hypertension (e.g.,signs/symptoms of
             splenomegaly, esophageal varices, etc.).

          -  Abnormal liver function test at screening, defined as aspartate aminotransferase (AST)
             and/or alanine aminotransferase (ALT) and/or alkaline phosphatase and/or gammaglutamyl
             transferase (GGT) ≥3 x the upper limit of normal (ULN), and/or total bilirubin ≥1.5 x
             the ULN at screening.
Clinical trial NCT03475706 (phase 2, status: completed)
Conditions: overactive bladder
ICD codes: N32.81
Drugs: solabegron immediate release tablets, low dose, solabegron immediate release tablets, high dose, matching placebo
SMILES: [H][C@](O)(CNCCNC1=CC(=CC=C1)C1=CC(=CC=C1)C(O)=O)C1=CC=CC(Cl)=C1, [H][C@](O)(CNCCNC1=CC(=CC=C1)C1=CC(=CC=C1)C(O)=O)C1=CC=CC(Cl)=C1, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Adult female subjects 18 to 80 years of age, with a ≥ 6-month history of symptoms of
             overactive bladder including: frequency, urgency, and urgency urinary incontinence.
             Subjects must provide written informed consent and either be of non-childbearing
             potential or of childbearing potential meeting specific criteria (e.g., negative
             pregnancy test, sexual inactivity, acceptable methods of birth control, and use of
             hormonal contraceptives).

        Exclusion Criteria:

          -  Subjects must have no history of pelvic or bladder disease, e.g., Grade 3/4 uterine
             prolapse, urogenital malignancy within the past 2 years, surgery for stress
             incontinence or pelvic prolapse repair within the past 6 months, or bladder injections
             with botulinum toxin at any time.

          -  Diabetes insipidus or poorly controlled Type 1 or Type 2 diabetes mellitus

          -  Cardiac conditions: prior cardiovascular events or procedures within 6 months of
             screening; congestive heart failure; abnormal ECG findings, including ECG QT
             correction interval (QTc) > 470 msec at the Screening Visit; systolic blood pressure ≥
             180 mmHg or diastolic blood pressure ≥100mmHg, or heart rate > 100 beats per minute.

          -  Abnormal tests of liver function

          -  History of prior infection due to HIV or hepatitis B or hepatitis C virus

          -  Allergy or hypersensitivity to solabegron or mirabegron

          -  Women of childbearing potential: breastfeeding, pregnant, or actively trying to become
             pregnant

          -  Participation in a trial of an investigational or marketed drug ≤ 30 days prior to the
             Screening Visit or in any clinical trial of an investigational drug that may affect
             urinary function within 3 months prior to Screening Visit.

          -  Inability to read, understand, or complete study-related materials.
Clinical trial NCT03478605 (phase 2, status: unknown status)
Conditions: emesis, vomiting, nausea post chemotherapy, nausea, chemotherapy-induced nausea and vomiting
ICD codes: R11.10, R11.12, R11.14, R11.11, K91.0, O21.2, O21.8, R11.0, R11.11, R11.2, D61.810
Drugs: olanzapine, aprepitant pill, ondansetron, dexamethasone
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN1C2=C(C3=CC=CC=C13)C(=O)C(CN1C=CN=C1C)CC2, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          1. High-emetogenic chemotherapy (HEC) regimen (e.g., cisplatin ≥70 mg/m2 or doxorubicin
             ≥60 mg/m2 or carboplatin AUC≥4). Patients that are prescribed less doses of mentioned
             agents are still allowed if another high-emetogenic drug will be administered (eg,
             doxorubicin plus cisplatin);

          2. Administration of HEC component only in first day of the cycle;

          3. No previous chemotherapy or radiotherapy;

          4. No concomitant quinolone antibiotics administration;

          5. ECOG PS ≤2;

          6. No nausea and vomiting 24 hours before enrollment;

          7. Adequate hepatic and renal function (eg, ALaT, ASaT ≤3 ULN, creatinine clearance ≥50
             ml/minute).

          8. No brain metastases, leptomeningeal carcinomatosis, and chronic diseases such as
             uncontrolled diabetes mellitus and chronic alcohol consumption.

          9. Subject willing to participate in the trial and provided informed consent form.

        Exclusion Criteria:

          1. Previous chemotherapy or radiotherapy;

          2. Moderate- or low- emetogenic chemotherapy;

          3. Multiday administration of HEC agents;

          4. ECOG PS >2;

          5. History of brain metastases, signs of symptoms of bowel obstruction;

          6. Nausea and/or vomiting of any genesis 24 hours before enrollment;

          7. Uncontrolled diabetes mellitus or other metabolic diseases; chronic alcohol
             consumption.

          8. Diseases and conditions interfere with subject ability to swallow the drug and to take
             oral medication;

          9. Concomitant therapy with olanzapine or other antipsychotic drugs; history of mental
             illness;

         10. Concomitant therapy with quinolone antibiotics;

         11. Contraindications for olanzapine or aprepitant administration;

         12. Intraperitoneal or intrapleural administration of HEC drugs;

         13. Inadequate hepatic and/or renal function.
Clinical trial NCT03482882 (phase 2, status: completed)
Conditions: treatment of depression in adults with parkinson's disease (pd)
ICD codes: G20
Drugs: pimavanserin
SMILES: CC(C)COC1=CC=C(CNC(=O)N(CC2=CC=C(F)C=C2)C2CCN(C)CC2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Can understand and provide signed informed consent, request for medical records and/or
             subject privacy form if applicable according to local regulations

          2. Has a clinical diagnosis of idiopathic Parkinson's disease with a minimum duration of
             1 year, defined as the presence of at least three of the following cardinal features,
             in the absence of alternative explanations or atypical features:

               1. rest tremor

               2. rigidity

               3. bradykinesia and/or akinesia

               4. postural and gait abnormalities

          3. Meets clinical criteria for depression with Parkinson's disease as listed in the
             NINDS/NIMH Guidelines

          4. If currently taking an anti-depressant, is being treated with only one SSRI or SNRI
             antidepressant at a dose within the US FDA-approved dose range. Subjects who are
             currently taking a second antidepressant or antidepressant augmentation agent at a
             sub-therapeutic dose or for an inadequate duration at Screening, and can be
             discontinued from this agent before the Baseline visit (in the opinion of the
             Investigator), may be eligible for the study.

          5. Is on a stable dose of anti-Parkinson's medication for 1 month prior to Screening

          6. If the subject is female, she must be of non-childbearing potential or agree to use
             two methods of clinically acceptable contraception

        Exclusion Criteria:

          1. Use of an antipsychotic within 3 weeks or 5 half-lives of Baseline (whichever is
             longer)

          2. Had a myocardial infarction within the 6 months prior to Screening

          3. Has a known personal or family history or symptoms of long QT syndrome

          4. Evidence of severe or medically significant hepatic or renal impairment on laboratory
             tests as assessed by the Investigator or Medical Monitor

          5. Has a history of PD psychosis, schizophrenia, or other psychotic disorder, or bipolar
             I or II disorder.

          6. Actively suicidal at Visit 1 (Screening) or Visit 2 (Baseline)

          7. Is pregnant or breastfeeding

          8. Has previously been treated with pimavanserin or is currently taking pimavanserin

          9. Has a sensitivity to pimavanserin or its excipients

         10. Is judged by the Investigator or the Medical Monitor to be inappropriate for the study

        Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to
        ensure that all criteria for study participation are met.
Clinical trial NCT03499223 (phase 2, status: completed)
Conditions: diabetes mellitus, diabetic retinopathy, macular edema
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9, H35.23, H35.20, H35.21, H35.22, E10.3553, E11.3553, E13.3553, H59.033, H34.8130, H59.031, H59.032, H59.039, H34.8110, H34.8120
Drugs: ranibizumab 0.5mg, thr-317 8mg, sham injection
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O, CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18 years or older

          -  Type 1 or type 2 Diabetes Mellitus

          -  CI-DME with central subfield thickness of ≥ 320μm on Spectralis® SD-OCT or ≥ 305μm on
             non Spectralis SD-OCT, in the study eye

          -  Anti-vascular endothelial growth factor (anti-VEGF) treatment naïve study eye, or poor
             or no response to prior treatment with ranibizumab in the study eye

          -  Reduced vision primarily due to DME, with BCVA ≤ 72 and ≥ 23 ETDRS letter score (≤
             20/40 and ≥ 20/320 Snellen equivalent) in the study eye

          -  Non-proliferative diabetic retinopathy of any stage in the study eye

          -  Written informed consent obtained from the subject prior to screening procedures

        Exclusion Criteria:

          -  Concurrent disease in the study eye, other than CI-DME, that could compromise BCVA,
             require medical or surgical intervention during the study period or could confound
             interpretation of the results

          -  Previous confounding treatments / procedures, or their planned / expected use during
             the study period for up to 30 days after the last administration of study treatment

          -  Any active ocular / intraocular infection or inflammation in either eye

          -  Aphakic study eye

          -  Poorly controlled Diabetes Mellitus

          -  Uncontrolled hypertension

          -  Pregnant or lactating female, or female of child-bearing potential not utilising an
             adequate form of contraception, or male of reproductive potential not utilising
             contraception
Clinical trial NCT03501550 (phase 2, status: completed)
Conditions: chronic hepatitis c
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: cdi-31244, sof/vel
SMILES: [H][C@](N=C(O)OC)(C(C)C)C(=O)N1[C@@]([H])(C)CC[C@@]1([H])C1=NC2=C(N1)C1=CC3=C(C=C1C=C2)C1=C(CO3)C=C(C=C1)C1=CN=C(N1)[C@]1([H])C[C@]([H])(COC)CN1C(=O)[C@]([H])(N=C(O)OC)C1=CC=CC=C1
Eligibility criteria:

        Key Inclusion Criteria:

        Documented chronic HCV GT 1 infection; Serum HCV RNA >1,000 IU/mL during screening; Absence
        of advanced fibrosis or cirrhosis

        Key Exclusion Criteria:

        Nursing or pregnant women; Active hepatitis B infection; Human immunodeficiency virus (HIV)
        infection; History of use of any HCV direct-acting antiviral therapy
Clinical trial NCT03506542 (phase 2, status: completed)
Conditions: glaucoma, cataract, wound heal
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H26.9, Q12.0, H59.023, H26.20, H26.40, H26.8, H59.021
Drugs: mitomycin c
SMILES: CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Cataract

          -  Primary open angle glaucoma or pseudoexfoliation glaucoma with progression of visual
             field loss and/or uncontrolled intraocular pressure levels with medication

        Exclusion Criteria:

          -  Difficulty in reading or speaking Polish

          -  Previous ocular surgery

          -  Pregnant and breastfeeding women

          -  Angle closure glaucoma

          -  Secondary glaucoma except pseudoexfoliation glaucoma

          -  Ocular diseases with excessive scarring

          -  Allergy to collagen or Mitomycin C
Clinical trial NCT03508648 (phase 2, status: terminated)
Conditions: stress urinary incontinence
ICD codes: N39.41, N39.46, N39.490, N39.491, N39.492, R32, R39.81
Drugs: gtx-024, matching placebo
SMILES: C[C@](O)(COC1=CC=C(C=C1)C#N)C(O)=NC1=CC(=C(C=C1)C#N)C(F)(F)F, CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Be one of the first 225 subjects who were randomly assigned to treatment in G201002
             (Phase 2 study) and have completed the 12-week treatment and 16-week durability
             periods

          -  Be able to read, understand, and provide written, dated informed consent prior to
             enrollment in the current study (within 2 weeks of completing G201002) and be likely
             to comply with the study protocol and communicate with study personnel about AEs and
             other clinically important information

          -  Agree to maintain a stable dose of any medication known to affect lower urinary tract
             function, including but not limited to anticholinergics, tricyclic antidepressants,
             beta-3 adrenergic agonists, or α-adrenergic blockers, throughout the duration of the
             study

        Exclusion Criteria:

          -  Starts any new treatment (medication, pelvic floor physical therapy, or other
             treatment known to impact the pelvic floor) after completing G201002 that is known or
             suspected to affect lower urinary tract function, including vaginal rejuvenation

          -  Has a current or past history of any physical condition that, in the investigator's
             opinion, might put the subject at risk or interfere with interpretation of study
             results
Clinical trial NCT03511066 (phase 2, status: unknown status)
Conditions: influenza a
ICD codes: J09.X1, J09.X3, J09.X9, J09.X2, A41.3, A49.2, B96.3
Drugs: ct-p27 dose1, ct-p27 dose2, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or Female subjects between the ages of 19 and 65 years, both inclusive

          -  Diagnosed with influenza A at screening.

          -  ≥38'C body temperature at screening

        Exclusion Criteria:

          -  Taking antiviral treatment for influenza or has a history of using these antivirals
             within 14 days prior to the administration of study drug.

          -  Positive influenza B or A+B infection
Clinical trial NCT03517566 (phase 2, status: terminated)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: placebo, zpl389, zpl389, zpl389, zpl389
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must give a written, signed and dated informed consent

          -  Chronic atopic dermatitis present for at least 1 year before Baseline

          -  Moderate to severe atopic dermatitis defined as per EASI, IGA and BSA.

          -  Documented recent history (within 6 months before the screening visit) of inadequate
             response to treatment with topical medications or for whom topical treatments are
             otherwise medically inadvisable

          -  Candidate for systemic treatment

        Exclusion Criteria:

          -  Any skin disease that would confound the diagnosis or evaluation of atopic dermatitis
             disease activity

          -  Use of other investigational drugs within 5 half-lives of enrollment, or within 30
             days or until the expected pharmacodynamic effect has returned to baseline, whichever
             is longer.

          -  History of hypersensitivity to any of the study drug constituents or to drugs of
             similar chemical classes.

          -  Participation in prior ZPL389 studies
Clinical trial NCT03517618 (phase 2, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: s-1+leucovorin
SMILES: FC1=CN(C2CCCO2)C(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          1. histologically or cytologically confirmed colorectal adenocarcinoma;

          2. metastatic and unresectable disease;

          3. presence of at least one measurable tumor lesion which is defined as lesion that can
             be measured in at least one dimension (longest diameter) with a minimum size of:

               1. 10mm by CT scan and MRI (no less than double the slice thickness and a minimum of
                  10mm);

               2. 20mm by conventional techniques;

          4. previously treatment to

               1. fluoropyrimidine, oxaliplatin and irinotecan;

               2. at least one targeted therapy

          5. adequate hematopoietic function which is defined as below:

               1. hemoglobin ≥ 9 g/dL;

               2. absolute neutrophil count (ANC) ≥ 1,500/mm3;

               3. platelet count ≥ 100,000/mm3;

          6. adequate hepatic function which is defined as below:

               1. total bilirubin ≤ 2 times upper limit of normal (ULN);

               2. hepatic transaminases (ALT and AST) ≤ 3 x ULN. If there are known liver
                  metastases, ALT or AST must be ≤ 5 x ULN;

          7. adequate renal function which is defined as below:

             a. serum creatinine ≤ 1.5 x ULN;

          8. age of 20 years or above;

          9. ECOG performance status 0-2;

         10. life expectancy of at least 12 weeks;

         11. ability to take oral medication;

         12. ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. history or known presence of brain metastasis;

          2. presence of mental disease or psychotic manifestation;

          3. significant medical conditions that is contraindicated to study medication or render
             patient at high risk from treatment complications based on investigator's discretion;

          4. presence of diarrhea ≥ grade 2 in common terminology criteria for adverse event
             version 4.0 (CTCAE v4.0);

          5. other malignancy within the past 5 years (different site or histology) except for
             adequately treated basal or squamous cell skin cancer or cervical cancer in situ;

          6. recent (within 30 days prior to study treatment) treatment of another investigational
             drug;

          7. pregnant women or nursing mothers, or positive pregnancy test for women of
             childbearing potential. Patients with childbearing potential should have effective
             contraception for both the patient and his or her partner during the study.
Clinical trial NCT03530293 (phase 2, status: terminated)
Conditions: tourette syndrome
ICD codes: F95.2
Drugs: valbenazine, placebo oral capsule
SMILES: COC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1, CC1=CC(O)=CC(C)=C1Cl
Reason stopped: 
    futility
  
Eligibility criteria:

        Inclusion Criteria:

          1. Have a clinical diagnosis of Tourette Syndrome (TS)

          2. Have at least moderate tic severity

          3. Have TS symptoms that impair school, occupational, and/or social function

          4. If using maintenance medication(s) for TS or TS spectrum diagnoses (e.g.
             obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD]),
             be on stable doses

          5. Be in good general health

          6. Adolescent subjects (12 to 17 years of age) must have a negative urine drug screen for
             amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or
             cannabinoids and a negative alcohol screen

          7. Subjects of childbearing potential who do not practice total abstinence must agree to
             use hormonal or two forms of nonhormonal contraception (dual contraception)
             consistently during the screening, treatment and follow-up periods of the study

        Exclusion Criteria:

          1. Have an active, clinically significant unstable medical condition within 1 month prior
             to screening

          2. Have a known history of long QT syndrome or cardiac arrhythmia

          3. Have a known history of neuroleptic malignant syndrome

          4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)

          5. Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors

          6. Have a blood loss ≥250 mL or donated blood within 30 days prior to screening

          7. Have a known history of substance dependence, substance (drug) or alcohol abuse

          8. Have a significant risk of suicidal or violent behavior

          9. Have initiated Comprehensive Behavioral Intervention for Tics (CBIT) during the
             screening period or at baseline or plan to initiate CBIT during the study

         10. Have received an investigational drug within 30 days before screening or plan to use
             an investigational drug (other than NBI-98854) during the study

         11. Have previously participated in an NBI-98854 clinical study, except for NBI-98854-1403
             or NBI-98854-1501.

         12. Have HIV, hepatitis B, or hepatitis C